SAT0240 Phase 3 trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE)

• Published in: Annals of the rheumatic diseases Vol. 76; no. Suppl 2; p. 864
• Main Authors: Merrill, J, Martin, RS, Shanahan, WR, Scheinberg, M, Kalunian, K, Wofsy, D
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 01.06.2017
• Subjects: Anti-DNA antibodies; Antimalarial agents; Antiphospholipid antibodies; BLyS protein; Cardiolipin; Clinical trials; Complement component C3; Complement component C4; Corticosteroids; Diarrhea; Erythema; Immunoglobulin G; Injection; Lupus; Lymphocytes B; Patients; Phospholipids; Population studies; Prednisone; Proteinuria; Respiratory tract diseases; Response rates; Stockholders; Systemic lupus erythematosus; Urinary tract

BackgroundTargeted, biologic inhibitors of B-cell Activating Factor (BAFF) have been evaluated in Phase 3 trials in over 5000 patients with SLE. Post hoc analyses of these studies identify lower placebo response and greater treatment effect using more stringent endpoints in patients entering with hi...